{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T12:44:49Z","timestamp":1747226689666,"version":"3.40.5"},"reference-count":0,"publisher":"Termedia Sp. z.o.o.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Med Sci"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>This study aimed to investigate the association between ANA and clinical characteristics as well as prognosis in a cohort of patients with anti-MDA5+ DM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and methods<\/jats:title><jats:p>We conducted a systematic retrospective study of medical records from Nanjing Medical University myositis associated interstitial lung disease (ILD) contort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 246 patients with anti-MDA5+ DM were enrolled in this study, with 28.5% males and 71.5% females. The median age was 53.0 years, the median disease duration was 2 months, and the median follow-up period was 12.0 months. ANA positivity rate at baseline was 52.4% in anti-MDA5+ DM patients. The ANA-positive group showed significantly higher positivity rates of anti-Ro52 antibodies (72.9% vs 54.7%, p=0.003) and anti-aminoacyl-tRNA synthetase (anti-ARS) antibodies (9.3% vs 2.6%, p=0.033) compared to the ANA-negative group, but lower ALT levels [39.0 (21.5, 79.3) vs 51.3 (36.5, 95.8), p=0.006].In a subgroup analysis of the ANA-positive group, MDA5+++ patients had a higher incidence of RPILD compared to the MDA5+ group (P=0.028). In the ANA negative subgroup analysis, MDA5+++ patients had a higher mortality rate and worse prognosis compared to the MDA5+ group (P=0.026). Multivariate COX regression analysis showed that elevated LDH levels and the presence of rapidly progressive interstitial lung disease (RPILD) were associated with poor prognosis in ANA-negative anti-MDA5+ DM patients [hazard ratios of 1.002 (95% CI 1.001, 1.003, P = 0.020) and 13.694 (95% CI 15.032, 37.267, P &lt; 0.001), respectively].<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>ANA is frequently found in patients with anti-MDA5+ DM. High titres of anti-MDA5 antibodies are associated with mortality and RPILD.<\/jats:p><\/jats:sec>","DOI":"10.5114\/aoms\/192272","type":"journal-article","created":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T15:40:56Z","timestamp":1729957256000},"source":"Crossref","is-referenced-by-count":0,"title":["Different antinuclear antibody subgroups of anti-melanoma differentiation-associated gene 5-positive dermatomyositis had variability in clinical presentation: a multicentre retrospective cohort study"],"prefix":"10.5114","author":[{"given":"Gang","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leixi","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenghua","family":"Weng","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6170-9601","authenticated-orcid":true,"given":"Zhichun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Second Affiliated Hospital of Soochow University, Suzhou, 215004, China, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3061","published-online":{"date-parts":[[2024,10,26]]},"container-title":["Archives of Medical Science"],"original-title":[],"link":[{"URL":"https:\/\/www.archivesofmedicalscience.com\/pdf-192272-115630","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.archivesofmedicalscience.com\/pdf-192272-115630","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T15:41:02Z","timestamp":1729957262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.archivesofmedicalscience.com\/Different-antinuclear-antibody-subgroups-of-anti-melanoma-differentiation-associated,192272,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,26]]},"references-count":0,"alternative-id":["192272"],"URL":"https:\/\/doi.org\/10.5114\/aoms\/192272","relation":{},"ISSN":["1734-1922","1896-9151"],"issn-type":[{"type":"print","value":"1734-1922"},{"type":"electronic","value":"1896-9151"}],"subject":[],"published":{"date-parts":[[2024,10,26]]}}}